November 9–11, 2026
KoelnmesseCologne, GermanyWhat You'll Discover
Dealmaking Confidence Returns
- 75% expect partnering and M&A appetite to increase over the next 12 months
- Yet investor risk aversion remains the primary constraint on biotech investment
Europe's Competitive Position Shifts
- 52% say US policy uncertainty has made Europe more attractive for building and partnering
- But Europe still scores only 2.8/5 as a dealmaking hub
Where Capital and Opportunity Converge
- Oncology/ADCs lead expected investment interest
- Healthy ageing, mental health and women's health identified as underinvested commercial opportunities
AI's Promise vs. Reality
- Current impact concentrated in back-office operations
- 57% expect AI to improve R&D productivity over the next 12–24 months
What Keeps Leaders Awake
- Access to capital, clinical data generation and scaling innovation emerge as top concerns
- Direct insights from CEOs and C-suite executives across the development spectrum
Why Download This Report?
- Benchmark your strategy against peer perspectives on partnering, investment and therapeutic priorities
- Understand investor expectations and what pharma partners scrutinise most when assessing opportunities
- Navigate geopolitical shifts affecting where and how biopharma companies build value
- Assess AI's real-world impact versus anticipated gains in R&D and clinical development
- Gain unfiltered C-suite perspectives on the challenges and opportunities shaping 2026–27
About the Survey
This survey represents a predominantly CEO-level audience across European and international biotech companies, spanning pre-clinical, clinical-stage and commercial organisations. Respondents include leaders from privately held and publicly listed companies headquartered across the UK, EU/EEA, Switzerland, US, China and Asia-Pacific.
The findings provide a timely snapshot of industry sentiment as biopharma enters a period of renewed dealmaking activity against a backdrop of continued capital discipline.